Терапия със стволови клетки за ALS (Странична амиотрофна склероза): разход, доказателства и как да изберете клиника

Как се изучава терапия със стволови клетки за ALS (Странична амиотрофна склероза)

Amyotrophic lateral sclerosis (ALS or motor neurone disease) is a neurodegenerative condition characterised by progressive loss of motor neurons in the spinal cord, brainstem, and motor cortex, resulting in paralysis and eventual respiratory failure. Pathogenic mechanisms involve excitotoxicity (glutamate accumulation), mitochondrial dysfunction, protein misfolding (SOD1, TDP-43, FUS), neuroinflammation, and non-cell-autonomous effects from glial cells. Neurogenic stem cells (derived from neural progenitor populations or induced pluripotent stem cells differentiated toward motor-neuron lineage) and placental mesenchymal stem cells deliver neuroprotective factors (GDNF, BDNF, HGF), suppress harmful microglial activation, and stabilise neuromuscular junctions. Sixty-five registered trials and ten actively recruiting centres explore intrathecal or intravenous cell delivery in rapidly progressive or early-onset ALS populations.

For the clinic's own description, see our partner clinic Stem Plus.

Какво показват доказателствата за ALS (Странична амиотрофна склероза)

Clinical trial safety data across >500 ALS recipients shows no treatment-limiting adverse events from intrathecal or intravenous cell infusion. Efficacy signals emerge from small phase II cohorts: decline in ALSFRS-R (disease rating scale) is slowed by 30–50% over 12 months in 30–45% of treated patients versus untreated historical controls; some maintain muscle strength for 6–12 months longer than expected disease trajectory. Markers of neuroinflammation (CSF cytokine levels, microglial activation on PET imaging) decline in responder subgroups. No completed pivotal trial has demonstrated survival prolongation; two large multi-centre efficacy trials are recruiting.

Видове клетки, използвани за ALS (Странична амиотрофна склероза)

Depending on assessment, a ALS (Motor Neurone Disease) protocol may draw on:

Цена на програма ALS (Странична амиотрофна склероза)

ALS stem-cell protocols in Sofia and international centres range €7,000–11,000 for treatment courses, incorporating 1–3 intrathecal cell injections (requiring lumbar puncture or reservoir implantation), baseline and serial neurological assessment (ALSFRS-R, manual muscle strength testing, respiratory function testing), neuroimaging (brain/spine MRI), and neurology consultation. Intrathecal procedures carry infection and neurological risks; surveillance and specialist neurologist involvement are mandatory. Repeat treatments and extended follow-up imaging accumulate costs substantially.

Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the ALS (Motor Neurone Disease) cost-by-country breakdown, or compare the best countries for ALS (Motor Neurone Disease) →

Before booking, check safety & regulation, the recovery climate, дали бихте могли да бъдете кандидат, and which cell type fits ALS (Motor Neurone Disease).

Въпроси, които хората задават за ALS (Странична амиотрофна склероза)

• Какъв е процентът на успех на терапията със стволови клетки за ALS (Странична амиотрофна склероза)?
• Колко време продължава терапията със стволови клетки за ALS (Странична амиотрофна склероза)?
• Одобрена ли е терапията със стволови клетки за ALS (Странична амиотрофна склероза) от FDA?
• Покрита ли е терапията със стволови клетки за ALS (Странична амиотрофна склероза) от застраховка?
• Коя е най-добрата страна за терапия със стволови клетки за ALS (Странична амиотрофна склероза)?
• Какво е времето на възстановление след терапия със стволови клетки за ALS (Странична амиотрофна склероза)?
• Стойна ли е терапията със стволови клетки за ALS (Странична амиотрофна склероза)?

Пълен ALS (Странична амиотрофна склероза) ЧЗВ → · Разбор на разходите ALS (Странична амиотрофна склероза) →

Източници и допълнително четене

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

• Open clinical trials for ALS (Motor Neurone Disease) (ClinicalTrials.gov) ↗
• Peer-reviewed research on PubMed ↗
• ISSCR patient guide — what to ask ↗
• FDA consumer warning on stem-cell therapies ↗
• EMA — advanced-therapy (ATMP) framework ↗
• Stem-cell therapy restores vision — long-term results — Stem Plus ↗
• iPS-cell breakthrough in spinal-cord injury — Stem Plus ↗

Useful tools & guides: Съм ли кандидат? · Какъв тип клетки? · Types of clinics & best countries · Калкулатор на разходи

Медицински преглед от редакционния екип на StemCellAtlas с Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) на партньорската клиника Stem Plus (София), спрямо ISSCR, FDA и EMA указания. Educational information, not medical advice; figures indicative.